Fractyl Health, Inc. (NASDAQ:GUTS) Given Average Recommendation of “Hold” by Brokerages

Shares of Fractyl Health, Inc. (NASDAQ:GUTS) have been given a consensus recommendation of “Hold” by the five brokerages that are presently covering the company, Marketbeat reports. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and three have given a buy rating to the company. The average 1-year target price among analysts that have issued ratings on the stock in the last year is $5.40.

A number of brokerages have weighed in on GUTS. HC Wainwright reaffirmed a “buy” rating and issued a $8.00 target price on shares of Fractyl Health in a research note on Friday, April 24th. Canaccord Genuity Group reaffirmed a “buy” rating and issued a $8.00 target price on shares of Fractyl Health in a research note on Thursday, March 26th. Morgan Stanley downgraded shares of Fractyl Health from an “overweight” rating to an “equal weight” rating and dropped their target price for the stock from $8.00 to $2.00 in a research note on Thursday, January 29th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Fractyl Health in a research note on Tuesday. Finally, Wall Street Zen raised shares of Fractyl Health from a “strong sell” rating to a “hold” rating in a research note on Saturday.

Fractyl Health Trading Down 9.8%

Shares of NASDAQ GUTS opened at $0.86 on Friday. Fractyl Health has a 1-year low of $0.38 and a 1-year high of $3.03. The company has a market cap of $136.53 million, a PE ratio of -0.67 and a beta of 2.11. The company has a current ratio of 4.28, a quick ratio of 4.78 and a debt-to-equity ratio of 1.41. The company has a 50-day moving average of $0.56 and a two-hundred day moving average of $1.13.

Fractyl Health (NASDAQ:GUTS) last announced its earnings results on Tuesday, May 12th. The company reported $0.06 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.17) by $0.23. As a group, equities analysts expect that Fractyl Health will post -0.66 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Fractyl Health

Institutional investors and hedge funds have recently modified their holdings of the business. Jane Street Group LLC bought a new stake in shares of Fractyl Health during the second quarter worth approximately $31,000. FNY Investment Advisers LLC bought a new stake in shares of Fractyl Health during the third quarter worth approximately $31,000. Jump Financial LLC bought a new stake in shares of Fractyl Health during the fourth quarter worth approximately $57,000. Scientech Research LLC bought a new stake in shares of Fractyl Health during the third quarter worth approximately $49,000. Finally, Prelude Capital Management LLC bought a new stake in shares of Fractyl Health during the third quarter worth approximately $55,000.

About Fractyl Health

Fractyl Health, Inc is a clinical-stage medical technology company focused on the development and commercialization of minimally invasive, endoscopic therapies for metabolic diseases. Headquartered in Lexington, Massachusetts, Fractyl is advancing treatments that target the underlying physiology of conditions such as type 2 diabetes, obesity and nonalcoholic fatty liver disease (NAFLD) by modifying the duodenal mucosa to improve metabolic control.

The company’s lead product, Revita® Duodenal Mucosal Resurfacing (Revita DMR), employs a catheter-based hydrothermal ablation technique to remodel the lining of the upper small intestine.